YKL-40 as a Potential Biomarker for the Differential Diagnosis of Alzheimer’s Disease
Abstract
:1. Introduction
2. Materials and Methods
3. Statistical Analysis
4. Publication Bias
5. Quality Evaluation
6. Description of Studies and Qualitative Findings
7. Qualitative Results and Statistical Analysis
7.1. AD vs. Normal Controls
7.2. MCI vs. Normal Controls
7.3. MCI AD vs. Normal Controls
7.4. MCIAD vs. MCI
7.5. AD vs. MCI
7.6. AD vs. MCIAD
8. Discussion
9. Therapeutic Strategies Targeting YKL-40 and Neuroinflammation
10. Limitations
11. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
Abbreviations
AD | Alzheimer’s disease |
APOE | Apolipoprotein E |
Ab1-42 | Beta-amyloid 1-42 |
CCL2 | Chemokine C-C motif ligand 2 |
CSF | Cerebrospinal fluid |
YKL-40 | Chitinase 3-like protein 1 |
CJD | Creutzfeldt-Jakob Disease |
DLB | Dementia with Lewy bodies |
FTD | Frontotemporal dementia |
mRNA | Messenger RNA |
MCI | Mild cognitive impairment |
NFT | Neurofibrillary tangles |
NFL | Neurofilament light chain |
NSAIDs | Non-steroidal anti-inflammatory drugs |
PD | Parkinson’s disease |
pre-AD | Preclinical Alzheimer’s disease |
pro-AD | Prodormal Alzheimer’s disease |
MCIAD | Progressive mild cognitive impairment |
tau | Tau protein |
VaD | Vascular demetia |
References
- Scheltens, N.M.; Galindo-Garre, F.; Pijnenburg, Y.A.; van der Vlies, A.E.; Smits, L.L.; Koene, T.; Teunissen, C.E.; Barkhof, F.; Wattjes, M.P.; Scheltens, P.; et al. The identification of cognitive subtypes in Alzheimer’s disease dementia using latent class analysis. J. Neurol. Neurosurg. Psychiatry 2015, 87, 235–243. [Google Scholar] [CrossRef]
- Blennow, K.; Dubois, B.; Fagan, A.M.; Lewczuk, P.; de Leon, M.J.; Hampel, H. Clinical utility of cerebrospinal fluid biomarkers in the diagnosis of early Alzheimer’s disease. Alzheimer’s Dement. 2015, 11, 58–69. [Google Scholar] [CrossRef] [Green Version]
- Holtzman, D.M. CSF biomarkers for Alzheimer’s disease: Current utility and potential future use. Neurobiol. Aging 2011, 32, 4–9. [Google Scholar] [CrossRef] [Green Version]
- World Alzheimer Report. The Global Impact of Dementia; Alzheimer’s Disease International: London, UK, 2015. [Google Scholar]
- Akiyama, H.; Barger, S.; Barnum, S.; Bradt, B.; Bauer, J.; Cole, G.M.; Cooper, N.R.; Eikelenboom, P.; Emmerling, M.; Fiebich, B.L.; et al. Inflammation and Alzheimer’s disease. Neurobiol. Aging 2010, 21, 383–421. [Google Scholar] [CrossRef]
- Johnson, L.V.; Leitner, W.P.; Rivest, A.J.; Staples, M.K.; Radeke, M.J.; Anderson, D.H. The Alzheimer’s A beta-peptide is deposited at sites of complement activation in pathologic deposits associated with aging and age-related macular degeneration. Proc. Natl. Acad. Sci. USA 2002, 99, 11830–11835. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Selkoe, D.J. Alzheimer’s disease: Genes, proteins, and therapy. Physiol. Rev. 2011, 81, 741–766. [Google Scholar] [CrossRef] [PubMed]
- Bonneh-Barkay, D.; Bissel, S.J.; Kofler, J.; Starkey, A.; Wang, G.; Wiley, C.A. Astrocyte and macrophage regulation of YKL-40 expression and cellular response in neuroinflammation. Brain Pathol. 2012, 22, 530–546. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Rehli, M.; Niller, H.H.; Ammon, C.; Langmann, S.; Schwarzfischer, L.; Andreesen, R.; Krause, S.W. Transcriptional regulation of CHI3L1, a marker gene for late stages of macrophage differentiation. J. Biol. Chem. 2003, 278, 44058–44067. [Google Scholar] [CrossRef] [Green Version]
- Rehli, M.; Krause, S.W.; Andreesen, R. Molecular characterization of the gene for human cartilage gp-39 (CHI3L1), a member of the chitinase protein family and marker for late stages of macrophage differentiation. Genomics 1997, 43, 221–225. [Google Scholar] [CrossRef]
- Johansen, J.S. Studies on serum YKL-40 as a biomarker in diseases with inflammation, tissue remodelling, fibroses and cancer. Dan. Med. Bull. 2006, 53, 172–209. [Google Scholar]
- Kirkpatrick, R.B.; Emery, J.G.; Connor, J.R.; Dodds, R.; Lysko, P.G.; Rosenberg, M. Induction and expression of human cartilage glycoprotein 39 in rheumatoid inflammatory and peripheral blood monocyte-derived macrophages. Exp. Cell Res. 1997, 237, 46–54. [Google Scholar] [CrossRef] [PubMed]
- Colton, C.A.; Mott, R.T.; Sharpe, H.; Xu, Q.; Van Nostrand, W.E.; Vitek, M.P. Expression profiles for macrophage alternative activation genes in AD and in mouse models of AD. J. Neuroinflam. 2006, 3, 27–39. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Muszyński, P.; Groblewska, M.; Kulczyńska-Przybik, A.; Kułakowska, A.; Mroczko, B. YKL-40 as a Potential Biomarker and a Possible Target in Therapeutic Strategies of Alzheimer’s Disease. Curr. Neuropharmacol. 2017, 15, 906–917. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Olsson, B.; Lautner, R.; Andreasson, U.; Öhrfelt, A.; Portelius, E.; Bjerke, M.; Hölttä, M.; Rosén, C.; Olsson, C.; Strobel, G.; et al. CSF and blood biomarkers for the diagnosis of Alzheimer’s disease: A systematic review and meta-analysis. Lancet Neurol. 2016, 15, 673–684. [Google Scholar] [CrossRef]
- Baldacci, F.; Lista, S.; Cavedo, E.; Bonuccelli, U.; Hampel, H. Diagnostic function of the neuroinflammatory biomarker YKL-40 in Alzheimer’s disease and other neurodegenerative diseases. Expert Rev. Proteom. 2017, 14, 285–299. [Google Scholar] [CrossRef]
- Wang, L.; Gao, T.; Cai, T.; Li, K.; Zheng, P.; Liu, J. Alzheimer’s Disease Neuroimaging Initiative. Cerebrospinal fluid levels of YKL-40 in prodromal Alzheimer’s disease. Neurosci. Lett. 2020, 715, 134658. [Google Scholar] [CrossRef]
- RStudio Team. RStudio: Integrated Development for R; RStudio; PBC: Boston, MA, USA, 2020; Available online: http://www.rstudio.com/ (accessed on 20 October 2021).
- Hozo, S.P.; Djulbegovic, B.; Hozo, I. Estimating the mean and variance from the median, range, and the size of a sample. BMC Med. Res. Methodol. 2005, 5, 13. [Google Scholar] [CrossRef] [Green Version]
- Rosén, C.; Andersson, C.H.; Andreasson, U.; Molinuevo, J.L.; Bjerke, M.; Rami, L.; Lladó, A.; Blennow, K.; Zetterberg, H. Increased Levels of Chitotriosidase and YKL-40 in Cerebrospinal Fluid from Patients with Alzheimer’s Disease. Dement. Geriatr. Cogn. Dis. Extra 2014, 4, 297–304. [Google Scholar] [CrossRef]
- Zhang, H.; Ng, K.P.; Therriault, J.; Kang, M.S.; Pascoal, T.A.; Rosa-Neto, P.; Gauthier, S. Alzheimer’s Disease Neuroimaging Initiative. Cerebrospinal fluid phosphorylated tau, visinin-like protein-1, and chitinase-3-like protein 1 in mild cognitive impairment and Alzheimer’s disease. Transl. Neurodegener 2018, 7, 23. [Google Scholar] [CrossRef] [Green Version]
- Antonell, A.; Mansilla, A.; Rami, L.; Lladó, A.; Irnzo, A.; Olives, J.; Balasa, M.; Sánchez-Valle, R.; Molinuevo, J.L. Cerebrospinal fluid level of YKL-40 protein in preclinical and prodromal Alzheimer’s disease. J. Alzheimer’s Dis. 2014, 42, 901–908. [Google Scholar] [CrossRef]
- Llorens, F.; Thüne, K.; Tahir, W.; Kanata, E.; Diaz-Lucena, D.; Xanthopoulos, K.; Kovatsi, E.; Pleschka, C.; Garcia-Esparcia, P.; Schmitz, M.; et al. YKL-40 in the brain and cerebrospinal fluid of neurodegenerative dementias. Mol. Neurodegener 2017, 12, 83. [Google Scholar] [CrossRef]
- Gispert, J.D.; Monté, G.C.; Falcon, C.; Tucholka, A.; Rojas, S.; Sánchez-Valle, R.; Antonell, A.; Lladó, A.; Rami, L.; Molinuevo, J.L. CSF YKL-40 and pTau181 are related to different cerebral morphometric patterns in early AD. Neurobiol. Aging 2016, 38, 47–55. [Google Scholar] [CrossRef]
- Mattsson, N.; Tabatabaei, S.; Johansson, P.; Hansson, O.; Andreasson, U.; Månsson, J.E.; Johansson, J.O.; Olsson, B.; Wallin, A.; Svensson, J.; et al. Cerebrospinal fluid microglial markers in Alzheimer’s disease: Elevated chitotriosidase activity but lack of diagnostic utility. Neuromolecular Med. 2011, 13, 151–159. [Google Scholar] [CrossRef]
- Hampel, H.; Toschi, N.; Baldacci, F.; Zetterberg, H.; Blennow, K.; Kilimann, I.; Teipel, S.J.; Cavedo, E.; Melo Dos Santos, A.; Epelbaum, S.; et al. Alzheimer Precision Medicine Initiative (APMI). Alzheimer’s disease biomarker-guided diagnostic workflow using the added value of six combined cerebrospinal fluid candidates: Aβ1-42, total-tau, phosphorylated-tau, NFL, neurogranin, and YKL-40. Alzheimer’s Dement. 2018, 14, 492–501. [Google Scholar] [CrossRef] [PubMed]
- Janelidze, S.; Hertze, J.; Zetterberg, H.; Landqvist Waldö, M.; Santillo, A.; Blennow, K.; Hansson, O. Cerebrospinal fluid neurogranin and YKL-40 as biomarkers of Alzheimer’s disease. Ann. Clin. Transl. Neurol. 2015, 3, 12–20. [Google Scholar] [CrossRef] [Green Version]
- Kester, M.I.; Teunissen, C.E.; Sutphen, C.; Herries, E.M.; Ladenson, J.H.; Xiong, C.; Scheltens, P.; van der Flier, W.M.; Morris, J.C.; Holtzman, D.M.; et al. Cerebrospinal fluid VILIP-1 and YKL-40, candidate biomarkers to diagnose, predict and monitor Alzheimer’s disease in a memory clinic cohort. Alzheimer’s Res. Ther. 2015, 7, 59. [Google Scholar] [CrossRef] [Green Version]
- Olsson, B.; Hertze, J.; Lautner, R.; Zetterberg, H.; Nägga, K.; Höglund, K.; Basun, H.; Annas, P.; Lannfelt, L.; Andreasen, N.; et al. Microglial markers are elevated in the prodromal phase of Alzheimer’s disease and vascular dementia. J. Alzheimer’s Dis. 2013, 33, 45–53. [Google Scholar] [CrossRef] [PubMed]
- Craig-Schapiro, R.; Perrin, R.J.; Roe, C.M.; Xiong, C.; Carter, D.; Cairns, N.J.; Mintun, M.A.; Peskind, E.R.; Li, G.; Galasko, D.R.; et al. YKL-40: A novel prognostic fluid biomarker for preclinical Alzheimer’s disease. Biol. Psychiatry 2010, 68, 903–912, Published Correction Appears in Biol. Psychiatry 2011, 69, 389. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Sutphen, C.L.; Jasielec, M.S.; Shah, A.R.; Macy, E.M.; Xiong, C.; Vlassenko, A.G.; Benzinger, T.L.; Stoops, E.E.; Vanderstichele, H.M.; Brix, B.; et al. Longitudinal Cerebrospinal Fluid Biomarker Changes in Preclinical Alzheimer Disease During Middle Age. JAMA Neurol. 2015, 72, 1029–1042. [Google Scholar] [CrossRef]
- Alcolea, D.; Vilaplana, E.; Pegueroles, J.; Montal, V.; Sánchez-Juan, P.; González-Suárez, A.; Pozueta, A.; Rodríguez-Rodríguez, E.; Bartrés-Faz, D.; Vidal-Piñeiro, D.; et al. Relationship between cortical thickness and cerebrospinal fluid YKL-40 in predementia stages of Alzheimer’s disease. Neurobiol. Aging 2015, 36, 2018–2023. [Google Scholar] [CrossRef]
- Rogers, J.; Kirby, L.C.; Hempelman, S.R.; Berry, D.L.; McGeer, P.L.; Kaszniak, A.W.; Zalinski, J.; Cofield, M.; Mansukhani, L.; Willson, P. Clinical trial of indomethacin in Alzheimer’s disease. Neurology 1993, 43, 1609–1611. [Google Scholar] [CrossRef] [PubMed]
- de Jong, D.; Jansen, R.; Hoefnagels, W.; Jellesma-Eggenkamp, M.; Verbeek, M.; Borm, G.; Kremer, B. No effect of one-year treatment with indomethacin on Alzheimer;s disease progression: A randomized controlled trial. PLoS ONE 2008, 3, e1475. [Google Scholar] [CrossRef] [PubMed]
- Breitner, J.C.; Baker, L.D.; Montine, T.J.; Meinert, C.L.; Lyketsos, C.G.; Ashe, K.H.; Brandt, J.; Craft, S.; Evans, D.E.; Green, R.C.; et al. Extended results of the Alzheimer’s disease antiinflammatory prevention trial. Alzheimer’s Dement. 2011, 7, 402–411. [Google Scholar] [CrossRef] [PubMed] [Green Version]
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Mavroudis, I.; Chowdhury, R.; Petridis, F.; Karantali, E.; Chatzikonstantinou, S.; Balmus, I.M.; Luca, I.S.; Ciobica, A.; Kazis, D. YKL-40 as a Potential Biomarker for the Differential Diagnosis of Alzheimer’s Disease. Medicina 2022, 58, 60. https://doi.org/10.3390/medicina58010060
Mavroudis I, Chowdhury R, Petridis F, Karantali E, Chatzikonstantinou S, Balmus IM, Luca IS, Ciobica A, Kazis D. YKL-40 as a Potential Biomarker for the Differential Diagnosis of Alzheimer’s Disease. Medicina. 2022; 58(1):60. https://doi.org/10.3390/medicina58010060
Chicago/Turabian StyleMavroudis, Ioannis, Rumana Chowdhury, Foivos Petridis, Eleni Karantali, Symela Chatzikonstantinou, Ioana Miruna Balmus, Iuliana Simona Luca, Alin Ciobica, and Dimitrios Kazis. 2022. "YKL-40 as a Potential Biomarker for the Differential Diagnosis of Alzheimer’s Disease" Medicina 58, no. 1: 60. https://doi.org/10.3390/medicina58010060